IDS Launches New Specialist Assays For IDS-iSYS
These launches bring the IDS-iSYS product range to a total of six specialist immunoassays in line with management expectations.
The launch of the IDS-iSYS product for the determination of PTH represents a major market opportunity for IDS. Together PTH and vitamin D regulate calcium in the body. Because of this, physicians frequently request both PTH and 25-Hydroxy Vitamin D tests on the same patient sample to give a better understanding of the underlying conditions.
The ability to offer both analytes on the iSYS for simultaneous analysis not only facilitates IDS’s entry into the PTH market, but also enhances the attraction of adopting IDS’s 25-Hydroxy Vitamin D to prospective customers.
PTH is a clinical biomarker almost invariably performed on automated systems, and recent research commissioned by IDS indicates a global market size slightly in excess of E100m.
IGF-1 is produced in the body in response to Growth Hormone (hGH) and is a major factor involved in the regulation of growth. Measuring IGF-1 is essential in identifying the cause of growth disorders such as restricted growth in children, and acromegaly (or gigantism) in adults.
The IDS-iSYS IGF-1 assay launch follows hGH as the second product to be developed in close collaboration with Martin Bidlingmaier of the Medizinische Klinik of Munich. IGF-1 and hGH are commonly measured together in the clinical situation, so once again, the ability to offer both tests simultaneously on the iSYS will significantly enhance the product offering. The US and European markets for IGF-1 immunoassay alone are estimated to be c. E10.5m.
Osteocalcin is the major non-collagenous protein of bone and is an accurate biomarker of bone formation. Its measurement provides valuable information about the rate of bone growth or the efficacy of therapy aimed at building bone or reducing bone loss. The IDS-iSYS N-Mid Osteocalcin assay measures a very stable form of osteocalcin. IDS estimate that the European market for osteocalcin is worth c. E3m.
These launches bring the IDS-iSYS product range to a total of six specialist immunoassays and are important contributions to the building of comprehensive Diagnostic Panels. The automated Bone and Skeletal panel of 25- Hydroxy Vitamin D, PTH, PINP and N- Mid Osteocalcin meets the prime needs of the bone physician, to be joined by CTX-I and bone-specific alkaline phosphatase in mid-2010. hGH and IGF-1 form the core of the growth panel, to be joined by IGFBP-3 in the near future.
New product development will continue throughout 2010 and 2011, and will add still more complementary IDSiSYS products from an R&D pipeline. These are expected to include Bioactive PTH, CTX-II, IGFBP-3 and Bone TRAP5b.
Roger Duggan, CEO of IDS, said: “These are very important products joining the iSYS range. Menu is a major issue in a laboratory manager’s decision to take on any instrument. Whilst the extraordinary growth in Vitamin D testing mandated automation in many labs, and permitted us to launch with a single product, these latest launches, on time and on budget, add enormous strength to our offering.”
Will the company benefit with the new launch?
Have your say and discuss with your peers on the InfoGrok community.
Participate by posting your comments now.